Nongonococcal bacterial infections are the most serious infections affecting the joints. Normal joints, diseased joints, and prosthetic joints are all vulnerable to bacterial infection. The fact that septic joints signal the presence of a potentially life-threatening infection cannot be overemphasized, nor can the importance of early diagnosis and prompt, effective therapy. Mortality rates among adults range from 10% to greater than 50%. Full recovery is possible, but poor outcomes are common among those with preexisting arthritis, especially rheumatoid arthritis (RA). This chapter discusses acute nongonococcal bacterial arthritis in adults. Septic arthritis in children, gonococcal joint infection, and septic bursitis are also briefly discussed.


Synovial Fluid Lyme Disease Septic Arthritis Reactive Arthritis Acute Rheumatic Fever 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kaandorp CJE, Van Schaardenburg D, Krijnen P, et al. Risk factors for septic arthritis in patients with joint disease: a prospective study. Arthritis Rheum 1995;38:1819–1825.CrossRefPubMedGoogle Scholar
  2. 2.
    Franz A, Webster AD, Furr PM, et al. Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Br J Rheumatol 1997;36:661–668.CrossRefPubMedGoogle Scholar
  3. 3.
    Ho G Jr. Pseudoseptic arthritis. R I Med 1994;77:7–9.PubMedGoogle Scholar
  4. 4.
    Dubost J, Fis I, Denis P, et al. Polyarticular septic arthritis. Medicine 1993;72:296–310.CrossRefPubMedGoogle Scholar
  5. 5.
    Epstein JH, Zimmermann B, Ho G Jr. Polyarticular septic arthritis. J Rheumatol 1986;13:1105–1107.PubMedGoogle Scholar
  6. 6.
    Post JC, Ehrlich GD. The impact of the polymerase chain reaction in clinical medicine. JAMA 2000;283:1544–1546.CrossRefPubMedGoogle Scholar
  7. 7.
    Ho G Jr. How best to drain an infected joint: will we ever know for certain? J Rheumatol 1993;20:2001–2003.PubMedGoogle Scholar
  8. 8.
    Kaandorp CJE, Krijnen P, Moens HJB, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum 1997;40:884–892.CrossRefPubMedGoogle Scholar
  9. 9.
    American Dental Association/American Academy of Orthopaedic Surgeons. Advisory statement: antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003;134:895–899.Google Scholar
  10. 10.
    Zimmermann B III, Mikolich DJ, Ho G Jr. Septic bursitis. Semin Arthritis Rheum 1995;24:391–410.CrossRefPubMedGoogle Scholar
  11. 1.
    Calabrese LH, Naides SJ. Viral arthritis. Infect Dis Clin North Am 2005;19:963–980.CrossRefPubMedGoogle Scholar
  12. 2.
    Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586–597.CrossRefPubMedGoogle Scholar
  13. 3.
    Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63(Suppl 2):ii18–ii24.CrossRefPubMedGoogle Scholar
  14. 4.
    Smith CA, Petty RE, Tingle AJ. Rubella virus and arthritis. Rheum Dis Clin North Am 1987;13:265–274.PubMedGoogle Scholar
  15. 5.
    Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep 2003;5:200–204.CrossRefPubMedGoogle Scholar
  16. 6.
    Sene D, Ghillani-Dalbin P, Limal N, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren’s syndrome. Ann Rheum Dis 2006;65:394–397.CrossRefPubMedGoogle Scholar
  17. 7.
    Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 2000;18:579–584.PubMedGoogle Scholar
  18. 8.
    Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089–2094.CrossRefPubMedGoogle Scholar
  19. 9.
    Vassilopoulos D, Calabrese L. Rheumatic aspects of human immunodeficiency virus infection and other immunodeficiency states. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, eds. Rheumatology. 4th ed. St. Louis: Mosby; 2006:26.1–26.9.Google Scholar
  20. 10.
    Calabrese L, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus (HIV) infection in the era of highly active antiretroviral therapy (HAART): emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005;35:166–174.CrossRefPubMedGoogle Scholar
  21. 1.
    Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004;113:1093–1101.PubMedGoogle Scholar
  22. 2.
    Dennis DT, Hayes EB. Epidemiology of Lyme borreliosis. In: Kahl O, Gray JS, Lane RS, Stanek G, eds. Lyme borreliosis: biology, epidemiology and control. Oxford: CABI Publishing; 2002:251–280.CrossRefGoogle Scholar
  23. 3.
    Lyme disease statistics. Centers for Disease Control Web site. Available at:
  24. 4.
    Bockenstedt LK. Lyme disease. In: Imboden JB, Hellmann DB, Stone JH, eds. Current diagnosis and treatment in rheumatology. 2nd ed. New York: McGraw-Hill. 2007:372–382.Google Scholar
  25. 5.
    James AM, Liveris D, Wormser GP, et al. Borrelia lonestari infection after a bite by an Amblyomma americanum tick. J Infect Dis 2001;183:1810–1814.CrossRefPubMedGoogle Scholar
  26. 6.
    Steere AC, Falk B, Drouin EE, et al. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 2003;48:534–550.CrossRefPubMedGoogle Scholar
  27. 7.
    Aquero-Rosenfeld ME, Wang G, Schwartz I, et al. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005;18:484–509.CrossRefGoogle Scholar
  28. 8.
    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089–1134.CrossRefPubMedGoogle Scholar
  29. 9.
    Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85–92.CrossRefPubMedGoogle Scholar
  30. 10.
    Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005;34:1340–1345.CrossRefPubMedGoogle Scholar
  31. 1.
    Leonard MKJ, Blumberg HM. Musculoskeletal tuberculosis. In: Schlossberg D, ed. Tuberculosis & nontuber-culous mycobacterial infections. 5th ed. New York: McGraw-Hill; 2006:242–263.Google Scholar
  32. 2.
    Martini M, Ouahes M. Bone and joint tuberculosis: a review of 652 cases. Orthopedics 1988;11:861–866.PubMedGoogle Scholar
  33. 3.
    Cormican L, Hammal R, Messenger J, Milburn HJ. Current difficulties in the diagnosis and management of spinal tuberculosis. Postgrad Med J 2006;82:46–51.CrossRefPubMedGoogle Scholar
  34. 4.
    Ridley N, Shaikh MI, Remedios D, Mitchell R. Radiology of skeletal tuberculosis. Orthopedics 1998;21:1213–1220.PubMedGoogle Scholar
  35. 5.
    Perronne C, Saba J, Behloul Z, et al. Pyogenic and tuberculous spondylodiskitis (vertebral osteomyelitis) in 80 adult patients. Clin Infect Dis 1994;19:746–750.PubMedGoogle Scholar
  36. 6.
    Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Pre-vention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.CrossRefPubMedGoogle Scholar
  37. 7.
    Garrido G, Gomez-Reino JJ, Fernandez-Dapica P, Palenque E, Prieto S. A review of peripheral tuberculous arthritis. Semin Arthritis Rheum 1988;18:142–149.CrossRefPubMedGoogle Scholar
  38. 8.
    Malaviya AN, Kotwal PP. Arthritis associated with tuberculosis. Best Pract Res Clin Rheumatol 2003;17:319–343.CrossRefPubMedGoogle Scholar
  39. 9.
    Allali F, Mahfoud-Filali S, Hajjaj-Hassouni N. Lymphocytic joint fluid in tuberculous arthritis. A review of 30 cases. Joint Bone Spine 2005;72:319–21.CrossRefGoogle Scholar
  40. 10.
    Dall L, Long L, Stanford J. Poncet’s disease: tuberculous rheumatism. Rev Infect Dis 1989;11:105–107.PubMedGoogle Scholar
  41. 11.
    Tinazzi E, Ficarra V, Simeoni S, Artibani W, Lunardi C. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006;26:481–488.CrossRefPubMedGoogle Scholar
  42. 12.
    Yangco BC, Espinoza CG, Germain BF. Nontuberculous mycobacterial joint infections. In: Espinosa L, Goldenberg D, Arnett F, Alarcon G, eds. Infections in the rheumatic diseases. Orlando: Grune & Stratton; 1988:139–157.Google Scholar
  43. 13.
    Gibson T, Ahsan Q, Hussein K. Arthritis of leprosy. Br J Rheumatol 1994;33:963–966.CrossRefPubMedGoogle Scholar
  44. 14.
    McGill PE. Geographically specific infections and arthritis, including rheumatic syndromes associated with certain fungi and parasites, Brucella species and Mycobacterium leprae. Best Pract Res Clin Rheumatol 2003;17:289–307.CrossRefPubMedGoogle Scholar
  45. 15.
    Kohli R, Hadley S. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 2005;19:831–851.CrossRefPubMedGoogle Scholar
  46. 16.
    Silveira LH, Cuellar ML, Citera G, Cabrera GE, Scopelitis E, Espinoza LR. Candida arthritis. Rheum Dis Clin North Am 1993;19:427–437.PubMedGoogle Scholar
  47. 17.
    Cuende E, Barbadillo C, Isasi C, Trujillo A, Andreu JL. Candida arthritis in adult patients who are not intravenous drug addicts: report of three cases and review of the literature. Semin Arthritis Rheum 1993;22:224–241.CrossRefPubMedGoogle Scholar
  48. 18.
    Perez-Gomez A, Prieto A, Torresano M, et al. Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 1998;27:226–244.CrossRefPubMedGoogle Scholar
  49. 19.
    Cuellar ML, Silveira LH, Citera G, Cabrera GE, Valle R. Other fungal arthritides. Rheum Dis Clin North Am 1993;19:439–455.PubMedGoogle Scholar
  50. 20.
    Peng SL. Rheumatic manifestations of parasitic diseases. Semin Arthritis Rheum 2002;31:228–247.CrossRefPubMedGoogle Scholar
  51. 1.
    Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685–694.CrossRefPubMedGoogle Scholar
  52. 2.
    Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992;268:2069–2073.Google Scholar
  53. 3.
    Zomorrodi A, Wald ER. Sydenham’s chorea in western Pennsylvania. Pediatrics 2006;117:e675–e679.CrossRefPubMedGoogle Scholar
  54. 4.
    Kaplan EL, Rothermel CD, Johnson DR. Antistreptolysin O and anti-deoxyribonuclease B titers: normal values for children ages 2 to 12 in the United States. Pediatrics 1998;101:86–88.CrossRefPubMedGoogle Scholar
  55. 5.
    Stollerman GH. Rheumatic fever in the 21st century. Clin Infect Dis 2001;33:806–814.CrossRefPubMedGoogle Scholar
  56. 6.
    Shulman ST, Stollerman G, Beall B, Dale JB, Tanz RR. Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis 2006;42:441–447.CrossRefPubMedGoogle Scholar
  57. 7.
    Wilson M, Schweitzer, MG, Lubschez R. The familial epidemiology of rheumatic fever. J Pediatr 1943;22:461–491.Google Scholar
  58. 8.
    Guedez Y, Kotby A, El-Demellawy M, et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation 1999;99:2784–2790.PubMedGoogle Scholar
  59. 9.
    Taranta A TS, Metrakos JD. Rheumatic fever in monozyogotic and dizygotic twins. Circulation 1959;20:778–792.Google Scholar
  60. 10.
    Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics 1995;96:758–764.PubMedGoogle Scholar
  61. 11.
    Mackie SL, Keat A. Poststreptococcal reactive arthritis: what is it and how do we know? Rheumatology (Oxford) 2004;43:949–954.CrossRefGoogle Scholar
  62. 12.
    Ahmed S, Ayoub EM, Scornik JC, Wang CY, She JX. Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles. Arthritis Rheum 1998;41:1096–1102.CrossRefPubMedGoogle Scholar
  63. 13.
    Herold BC, Shulman ST. Poststreptococcal arthritis. Pediatr Infect Dis J 1988;7:681–682.CrossRefPubMedGoogle Scholar
  64. 14.
    Shulman ST, Ayoub EM. Poststreptococcal reactive arthritis. Curr Opin Rheumatol 2002;14:562–565.CrossRefPubMedGoogle Scholar
  65. 15.
    Ayoub EM, Ahmed S. Update on complications of group A streptococcal infections. Curr Probl Pediatr 1997;27:90–101.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • George HoJr
    • 1
  1. 1.Department of Internal Medicine, Division of RheumatologyBrody School of Medicine at East Carolina UniversityGreenvilleUSA

Personalised recommendations